Genomics plc, an analysis company developing algorithms, data resources, and software on genetic variation and human disease, has entered into a collaboration with Biogen to refine drug target selection through the use of sophisticated analysis of human genetic data.
 
Biogen will leverage findings from Genomics’ integrated database and analysis tools, which will be used to guide R&D regarding the likely efficacy and safety of its intended drug targets.
 
Genomics’ platform combines algorithms and software with the company’s genome-phenome database and analytical expertise to uncover the relationships between genetic variation and human health outcomes. 
 
John Colenutt, chief executive officer, Genomics plc, said, “This agreement highlights the growing commitment within the pharmaceutical and biotech industries to systematically use human genetic data in research to increase the chance of success in drug development. With our proprietary technology, integrated database and tools, Genomics is ideally positioned to support pharma and biotech companies in this area.”
 
Sally John, vice president, Computational Biology and Genomics, Biogen, said, “At Biogen we firmly believe that genetic information can be a powerful tool in assessing potential drug targets. We are delighted to collaborate with the world-leading analysts at Genomics, and to benefit from their unique integrated genome-phenome database.”